6/23/2014 11:45:39 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“RegeneRx”) and Lee’s Pharmaceutical Holdings Ltd. (“Lee’s”) today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China.
Help employers find you! Check out all the jobs and post your resume.
comments powered by